Insulin Glargine 300 Units/mL Effectiveness in Patients with T2DM Uncontrolled by Basal Insulin in Real-Life Settings in the Czech Republic
| Autor: | Milan Flekač, Petr Jelínek, Jana Maskova, Martin Prázný |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases business.industry Insulin glargine Incidence (epidemiology) Basal insulin nutritional and metabolic diseases 02 engineering and technology Type 2 diabetes Hypoglycemia medicine.disease Gastroenterology chemistry.chemical_compound chemistry 020204 information systems Internal medicine 0202 electrical engineering electronic engineering information engineering medicine Glycated hemoglobin medicine.symptom business Weight gain Glycemic medicine.drug |
| Zdroj: | Journal of Diabetes Mellitus. 10:109-123 |
| ISSN: | 2160-5858 2160-5831 |
| DOI: | 10.4236/jdm.2020.103010 |
| Popis: | Introduction: To evaluate the clinical effectiveness of Gla-300 units/mL (Gla-300) in the treatment of patients with type 2 diabetes (T2DM) uncontrolled by basal insulin in real-life clinical settings in the Czech Republic (TOPAZ study). Methods: TOPAZ was a prospective, multi-center, non-interventional, 6-month study. Of the 312 patients screened, 289 were evaluated at month 6. The primary objective was the change of HbA1c after 6 months. The proportion of patients with HbA1c Results: HbA1c decreased significantly after 6 months (mean change 0.9% ± 1.1% DCCT [−9.9 ± 11.6 mmol/mol], p −1.8 ± 3.1 mmol/L) as well as the incidence of hypoglycemia decreased by 49% (p 0.0001) while no weight gain was observed. No significant safety signals were identified. Conclusion: In a real-life setting, switching to Gla-300 in T2DM patients uncontrolled with other basal insulin was associated with improved glycemic control and reduced risk of hypoglycemia without weight gain, while patients’ satisfaction with treatment increased. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|